Pulse Biosciences reports 96% one-year success in nPulse AF catheter study

• Pulse Biosciences presented updated late-breaking clinical data on April 25, 2026 at Heart Rhythm 2026 from its first-in-human feasibility study of nPulse cardiac catheter system for atrial fibrillation.
• Follow-up expanded to 95 patients at 6 months, 53 patients at 12 months, with results showing sustained effectiveness over time.
• Data indicated durable rhythm control outcomes at one year, supporting potential for a competitive long-term performance profile.
• Procedures remained efficient across sites, reinforcing a workflow that could support broader adoption if confirmed in later-stage studies.
• Safety profile remained favorable across 177 treated patients, with a low rate of serious adverse events tied to primary safety endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-013383), on April 27, 2026, and is solely responsible for the information contained therein.